Research summaries for everyoneNot medical advice
BPC-157 research reference vial, Elevated Pharma

Research reference · Tissue Repair

BPC-157

BPC-157 is a synthetic 15-residue peptide studied mostly in rodent models of tissue and gut injury. In 2026 it moved from FDA’s restricted list to an HHS interim compounding policy, though it remains unapproved.

Published by Elevated Pharma ·

Tissue RepairPreclinical literature / FDA review

Identity

What is BPC-157?

A synthetic pentadecapeptide, also called body protection compound 157.

Research context

What has BPC-157 been studied for?

The record is mainly preclinical. Human data are limited to small case series; two 2026 systematic reviews and an orthopaedic review conclude that controlled human evidence is lacking.

Evidence boundary

What does the research not show?

Preclinical findings do not establish human effectiveness or safety, and evidence for one compound does not transfer to a blend.

U.S. status · November 7, 2026

Is BPC-157 FDA-approved?

FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 8–6, one abstention; nominated for ulcerative colitis). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.

Research updates

What’s new

Dated developments for BPC-157, newest first. See all research updates.

  1. HHS interim compounding policy

    HHS published an enforcement-discretion policy covering BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 for licensed pharmacies and physicians. Comments close November 13, 2026.

    Read the source
  2. Orthopaedic review

    A JAAOS review of BPC-157, thymosin beta-4 and TB-500 finds mostly preclinical evidence.

    Read the source
  3. FDA advisory committee votes

    FDA’s Pharmacy Compounding Advisory Committee voted on seven peptides over July 23–24, recommending six and declining emideltide (DSIP).

    Read the source
  4. Category 2 removals

    FDA announced the removal of 12 peptide substances from its Category 2 compounding list, effective about April 22, 2026. Removal is not approval.

    Read the source

Key studies

The main BPC-157 research

Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.

Search all 224 PubMed records for BPC-157 · Counts and selections checked November 7, 2026.

Reference identifiers

BPC-157 identity data

Database identity describes the reference substance, not any specific material or lot.

Primary name
BPC-157
Also indexed as
Body protection compound 157
Molecular formula
C62H98N16O22
Molecular mass
1419.5 g/mol
PubChem CID
9941957

Official & primary sources

Regulatory and database records

Citation does not imply an Elevated Pharma partnership or endorsement.